Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) shot up by more than 20% in pre-market trading on Friday after the clinical-stage biopharmaceutical company announced positive topline results for oral ANAVEX2-73 (blarcamesine). Anavex2-73 is the company’s Alzheimer’s disease candidate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Phase 2b clinical study achieved both the primary and secondary endpoints with statistically significant results. This was a randomized, double-blind, multicenter, placebo-controlled clinical trial with 509 patients enrolled in the study.
Wall Street analysts are bullish about AVXL stock with a Strong Buy consensus rating based on a unanimous four Buys.